| P50 | author | Marco Persico | Q38359854 |
| | Caterina Fattorusso | Q56794622 |
| | Antonio Di Dato | Q58895405 |
| | Alessia Camperchioli | Q58895654 |
| | Lella Petrella | Q85293389 |
| | Giovanni Scambia | Q91909477 |
| | Ettore Novellino | Q38359645 |
| P2093 | author name string | Ajay Kumar | |
| | Vineet Kumar | |
| | Cristiano Ferlini | |
| | Antonella Pepe | |
| | Nausicaa Orteca | |
| | Sanjay V Malhotra | |
| | Antonio E Alegria | |
| | Sakkarapalayam Mahalingam | |
| | Mirko Andreoli | |
| | Marisa Mariani | |
| | Laima Sevciunaite | |
| P2860 | cites work | Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate | Q40621800 |
| | Synthesis of Novel Functionalized 4-Aza-2,3-Didehydropodophyllotoxin Derivatives with Potential Antitumor Activity | Q41474287 |
| | Mechanism of GTPase-activity-induced self-assembly of human guanylate binding protein 1. | Q43069881 |
| | Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. | Q43591585 |
| | Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation | Q45130002 |
| | Merging chemical and biological space: Structural mapping of enzyme binding pocket space. | Q51853796 |
| | Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. | Q54756726 |
| | Biological evaluation on different human cancer cell lines of novel colchicine analogs | Q73096222 |
| | A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives | Q74779776 |
| | Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins | Q27621403 |
| | Triphosphate structure of guanylate-binding protein 1 and implications for nucleotide binding and GTPase mechanism | Q27626880 |
| | Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? | Q27690752 |
| | Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer | Q28236320 |
| | Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? | Q28250433 |
| | Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 | Q28254548 |
| | Tubulins as therapeutic targets in cancer: from bench to bedside | Q28261265 |
| | Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region | Q28263775 |
| | Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? | Q28265906 |
| | Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes | Q28298601 |
| | How guanylate-binding proteins achieve assembly-stimulated processive cleavage of GTP to GMP | Q28299939 |
| | The eukaryotic linear motif resource ELM: 10 years and counting | Q28660725 |
| | The NCI60 human tumour cell line anticancer drug screen | Q29614975 |
| | Small-molecule inhibitors of protein-protein interactions: progressing towards the dream | Q29617758 |
| | Podophyllotoxin | Q30052864 |
| | Use of COMPARE analysis to discover functional analogues of bleomycin | Q30306128 |
| | Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules | Q30496972 |
| | Site-directed, Ligase-Independent Mutagenesis (SLIM): a single-tube methodology approaching 100% efficiency in 4 h. | Q33209678 |
| | Privileged structure-based quinazolinone natural product-templated libraries: identification of novel tubulin polymerization inhibitors | Q33226224 |
| | Differential targeting of Gbetagamma-subunit signaling with small molecules | Q33240532 |
| | The importance of discerning shape in molecular pharmacology | Q33789461 |
| | A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation | Q34731493 |
| | N-hydroxyethyl-4-aza-didehydropodophyllotoxin derivatives as potential antitumor agents | Q35753083 |
| | Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters | Q36508381 |
| | How do microtubule-targeted drugs work? An overview | Q37065359 |
| | Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? | Q37073084 |
| | Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs | Q37903716 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| P304 | page(s) | 7916-7932 | |
| P577 | publication date | 2014-09-26 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells | |
| P478 | volume | 57 | |